MAY 21, 2020 10:40 AM PDT

Molecular 'Switch' Makes Autoimmune Drugs Fight Cancer

WRITTEN BY: Annie Lennon

Researchers from the Antibody and Vaccine Group at the University of Southampton, England, have identified a way to repurpose antibody-based autoimmunity drugs to treat cancer. Turning on a simple molecular 'switch,' they were able to successfully use these drugs to treat cancer in preclinical trials.

CD40 is a molecule found on the surface of immune cells that is known to play a role in autoimmunity disorders and cancer. Overstimulation of the molecule increases the chance of the immune system attacking healthy cells. Meanwhile, under-stimulation allows cancerous tumor cells to sneak past the immune system and multiply. Due to its role in both diseases, CD40 is a drug target for both autoimmune and cancer treatments. 

Although drugs are currently under development to either activate or suppress CD40, until recently, they were developed in isolation of each other. But his may no longer need to be the case. Researchers have found a way to invert the function of CD40 by merely modifying the 'constant' domain of different antibody treatments. 

Using this inversion 'trick' in the antibody drugs, they were able to change drugs from being CD40 suppressors (for autoimmune disorders) to CD40 activators (for cancer). One, in particular, was able to stimulate the immune system to fight cancer more effectively in preclinical trials than the best CD40-targeting antibody currently in clinical trials.  

"Our findings build on a history of CD40 research here in Southampton and were surprising and exciting in equal measure," said Professor Mark Cragg, senior author of the study. "Taking an antibody that suppresses the immune system and turning it on its head, to activate the immune system for cancer through a relatively simple process is unprecedented. More than that, the same approach could be used for other immune targets and we look forward to seeing testing this in the near future".

 

Sources: Medical Xpress, Cancer Cell

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JUL 21, 2020
Cardiology
Investigating New Anti-Blood Clotting Treatments
JUL 21, 2020
Investigating New Anti-Blood Clotting Treatments
When it comes to your cardiovascular health, it is important to look at more than just your heart. The cardiovascular sy ...
AUG 04, 2020
Neuroscience
Transcranial Stimulation Disrupts Fearful Memories
AUG 04, 2020
Transcranial Stimulation Disrupts Fearful Memories
Disrupting negative memory formation has been a challenge for years- involving treatments ranging from psychotherapy to ...
AUG 05, 2020
Drug Discovery & Development
New Drug Prevents Inherited Alzheimer's in Mice
AUG 05, 2020
New Drug Prevents Inherited Alzheimer's in Mice
Researchers at the Salk Institute have developed a new drug candidate that has successfully prevented Alzheimer's-re ...
AUG 17, 2020
Drug Discovery & Development
How Do Drugs Treat Parasitic Infections?
AUG 17, 2020
How Do Drugs Treat Parasitic Infections?
How Do Medications Deal With Parasitic Infections? Researchers have been curious to know how a common medication battles ...
SEP 20, 2020
Cell & Molecular Biology
Revealing the Structure of Hallucinogens Bound to Their Receptor
SEP 20, 2020
Revealing the Structure of Hallucinogens Bound to Their Receptor
Recent studies have demonstrated that hallucinogenic drugs like LSD, psilocybin, and mescaline have therapeutic potentia ...
SEP 21, 2020
Drug Discovery & Development
WHO Endorses Clinical Trials for Herbal Medicines to Treat COVID-19
SEP 21, 2020
WHO Endorses Clinical Trials for Herbal Medicines to Treat COVID-19
The World Health Organization has endorsed a protocol to put African herbal medicines through clinical trials as possibl ...
Loading Comments...